Clinical Trials Logo

Clinical Trial Summary

This study is 8 weeks long and involves subjects taking memantine or placebo. If they are randomly assigned to the memantine arm and are eligible to participate in the study, they will begin by taking 10mg once daily of memantine for two weeks, then 20mg for the remaining six weeks. Efficacy and safety measures will be performed at each visit. Participants will be randomized to receive either memantine or placebo on a 1:1 basis. This blinding will be maintained by the IDS pharmacy at the University of Chicago.


Clinical Trial Description

The goal of the proposed study is to evaluate the efficacy and safety of memantine in 100 subjects with DSM-5 trichotillomania (TTM) or skin picking disorder (SPD). The hypothesis to be tested is that memantine will be more effective and well tolerated in adults with trichotillomania or skin picking disorder compared to placebo. The proposed study will provide needed data on the treatment of a disabling disorder where there are not any current treatments options. This will be one of few studies assessing the use of pharmacotherapy for the treatment of TTM and SPD in adults. Assessing the efficacy and safety of memantine will help inform clinicians about additional treatment options for adults suffering from this disorder. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04792645
Study type Interventional
Source University of Chicago
Contact
Status Completed
Phase Phase 2
Start date June 15, 2021
Completion date July 8, 2022

See also
  Status Clinical Trial Phase
Recruiting NCT05207085 - Efficacy of Valbenazine for the Treatment of Trichotillomania in Adults Phase 2
Recruiting NCT05003401 - Leveraging Technological Advancements to Improve the Treatment of Trichotillomania N/A
Completed NCT04455152 - Self-control and Body-focused Repetitive Behaviors Phase 1
Not yet recruiting NCT05545891 - Aripiprazole in Body Focused Repetitive Behaviors Phase 2
Recruiting NCT05796752 - Behavioral Treatment and Memantine in Body Focused Repetitive Behaviors Phase 2/Phase 3
Recruiting NCT04978428 - Epidiolex in Obsessive Compulsive Disorder and Related Disorders Phase 2